Akari Therapeutics (AKTX) Net Equity Issued and Repurchased (2012 - 2025)
Akari Therapeutics (AKTX) reported Net Equity Issued and Repurchased of $479560.0 for Q4 2025, down 84.67% on a YoY basis from $3.1 million in Q4 2024, and down 89.99% sequentially from $4.8 million in Q2 2025.
Akari Therapeutics (AKTX) Net Equity Issued and Repurchased (2012 - 2025) Analysis & Trends
Akari Therapeutics (AKTX) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $479560.0 in Q4 2025.
- For the quarter ending Q4 2025, Net Equity Issued and Repurchased fell 84.67% year-over-year to $479560.0; the trailing twelve-month figure through Dec 2025 stood at $6.4 million (down 46.18% YoY), and the FY2025 full-year result was $10.7 million, down 9.23% from the prior year.
- Net Equity Issued and Repurchased eased to $479560.0 in Q4 2025, from $4.8 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $7.1 million in Q2 2024 to a low of -$133000.0 in Q3 2024.
- A 4-year average of $2.8 million and a median of $1.8 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
- Peak annual rise in Net Equity Issued and Repurchased reached 73.78% in 2024, while the deepest fall reached 107.82% in 2024.
- Tracing AKTX's Net Equity Issued and Repurchased over 4 years: stood at $5.4 million in 2021, then tumbled by 66.67% to $1.8 million in 2023, then soared by 73.78% to $3.1 million in 2024, then plunged by 84.67% to $479560.0 in 2025.
- Business Quant data shows AKTX's Net Equity Issued and Repurchased at $479560.0 in Q4 2025, $4.8 million in Q2 2025, and $1.1 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 141.90 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 479,560.00 |
| Dec 31, 2025 | 479,560.00 |
| Jun 30, 2025 | 4.79 Mn |
| Jun 30, 2025 | 4.79 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 3.13 Mn |
| Dec 31, 2024 | 3.13 Mn |
| Sep 30, 2024 | -133,000.00 |
| Sep 30, 2024 | -133,000.00 |
| Jun 30, 2024 | 7.12 Mn |
| Jun 30, 2024 | 7.12 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Dec 31, 2023 | 1.80 Mn |
| Dec 31, 2023 | 1.80 Mn |
| Sep 30, 2023 | 1.70 Mn |
| Sep 30, 2023 | 1.70 Mn |
| Mar 31, 2023 | 3.50 Mn |
| Mar 31, 2023 | 3.50 Mn |